Cat. No.: HY-14397G

Indomethacin (GMP)

(Synonyms: Indometacin (GMP))

Indomethacin (GMP) is Indomethacin (HY-14397) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Indomethacin (Indometacin) is a potent, orally active COX1/2 inhibitor with IC₅₀ values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin has anticancer activity and anti-infective activity. Indomethacin can be used for cancer, inflammation and viral infection research.

For research use only. We do not sell to patients.

CAS No.: 53-86-1
Formula: C₁₉H₁₆ClNO₄
Molecular Weight:357.79

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (277 KB)

Indomethacin (GMP) Chemical Structure

CAS No.: 53-86-1

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All Antibiotic Isoforms :

All COX Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
2008	IC₅₀	12 μM Compound: Indomethacin	Inhibition of human MRP1 in human 2008 cells Inhibition of human MRP1 in human 2008 cells	[PMID: 18707884]
2008	IC₅₀	12.6 μM Compound: indometacin	Inhibition of MRP1 expressed in human 2008 cells assessed as calcein AM accumulation by cell based assay Inhibition of MRP1 expressed in human 2008 cells assessed as calcein AM accumulation by cell based assay	[PMID: 21354800]
A549	IC₅₀	>100 μM Compound: Indomethacin	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 20583750]
A549	IC₅₀	40.6 μM Compound: indomethacin	Inhibition of mPGES-1 in human IL-1beta-stimulated A549 cell microsomes assessed as inhibition of PGE2 formation from PGH2 after 15 mins by RP-HPLC analysis Inhibition of mPGES-1 in human IL-1beta-stimulated A549 cell microsomes assessed as inhibition of PGE2 formation from PGH2 after 15 mins by RP-HPLC analysis	[PMID: 22992107]
A549	IC₅₀	>50 μM Compound: Indometacin	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32987314]
A549	IC₅₀	>50 μM Compound: Indometacin	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32987314]
A549	IC₅₀	>50 μM Compound: Indometacin	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32987314]
Bel-7402	IC₅₀	>100 μM Compound: Indomethacin	Antiproliferative activity against human Bel7402 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human Bel7402 cells after 72 hrs by CCK-8 assay	[PMID: 28301815]
Bel7402/5-FU	IC₅₀	>100 μM Compound: Indomethacin	Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by CCK-8 assay Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by CCK-8 assay	[PMID: 28301815]
BJ	IC₅₀	>50 μM Compound: C	Cytotoxicity against human BJ cells after 72 hrs by luminescence assay Cytotoxicity against human BJ cells after 72 hrs by luminescence assay	[PMID: 20129783]
BV-2	IC₅₀	7.1 μM Compound: Indomethacin	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay	[PMID: 24042007]
BV-2	IC₅₀	35.7 μM Compound: indomethacin	Inhibition of LPS-activated nitric oxide production in mouse BV2 cells pre-treated for 60 mins before LPS challenge for 24 hrs by Griess assay Inhibition of LPS-activated nitric oxide production in mouse BV2 cells pre-treated for 60 mins before LPS challenge for 24 hrs by Griess assay	[PMID: 26348503]
BV-2	IC₅₀	34.5 μM Compound: Indomethacin	Antineuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 10 mins followed by LPS stimulation for 24 hrs by Griess assay Antineuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 10 mins followed by LPS stimulation for 24 hrs by Griess assay	[PMID: 27120704]
BV-2	IC₅₀	19.51 μM Compound: Indomethacin	Antineuroinflammatory activity in LPS-induced mouse BV-2 cells assessed as inhibition of NO production by griess assay Antineuroinflammatory activity in LPS-induced mouse BV-2 cells assessed as inhibition of NO production by griess assay	[PMID: 37530709]
BV-2	IC₅₀	15.2 μM Compound: Indomethacin	Anti-inflammatory activity in mouse BV-2 cells assessed as reduction in LPS-induced NO production Anti-inflammatory activity in mouse BV-2 cells assessed as reduction in LPS-induced NO production	[PMID: 37683361]
BV-2	IC₅₀	55.44 μM Compound: Indomethacin	Anti-inflammatory activity in mouse BV-2 cells assessed as reduction in LPS-induced NO production pretreated for 1 hr followed by LPS-stimulation and measured after 18 hrs by 2,3-diaminonaphthalene reagent based fluorescence analysis Anti-inflammatory activity in mouse BV-2 cells assessed as reduction in LPS-induced NO production pretreated for 1 hr followed by LPS-stimulation and measured after 18 hrs by 2,3-diaminonaphthalene reagent based fluorescence analysis	[PMID: 37683361]
CHO	IC₅₀	0.018 μM Compound: Indomethacin	In vitro inhibitory potency against human COX-1 in stably transfected chinese hamster ovary (CHO) cells In vitro inhibitory potency against human COX-1 in stably transfected chinese hamster ovary (CHO) cells	[PMID: 10576684]
CHO	IC₅₀	0.026 μM Compound: Indomethacin	In vitro inhibitory potency against human COX-2 in stably transfected chinese hamster ovary (CHO) cells In vitro inhibitory potency against human COX-2 in stably transfected chinese hamster ovary (CHO) cells	[PMID: 10576684]
CHO	IC₅₀	0.026 μM Compound: Indomethacin	Inhibition of PGE-2 production in CHO cells expressing human COX-2. Inhibition of PGE-2 production in CHO cells expressing human COX-2.	[PMID: 10576685]
CHO	IC₅₀	3 μM Compound: Indomethacin	TP_TRANSPORTER: inhibition of Adefovir uptake in OAT1-expressing CHO cells TP_TRANSPORTER: inhibition of Adefovir uptake in OAT1-expressing CHO cells	[PMID: 10991954]
CHO	IC₅₀	25 μM Compound: 5	Modulation of gamma-secretase-mediated cleavage of human APP expressed in CHO cells with human presenilin-1 assessed as inhibition of amyloid beta42 production after 24 hrs by ELISA Modulation of gamma-secretase-mediated cleavage of human APP expressed in CHO cells with human presenilin-1 assessed as inhibition of amyloid beta42 production after 24 hrs by ELISA	[PMID: 20503989]
CHO	IC₅₀	25 μM Compound: 2	Modulation of gamma-secretase expressed in CHO cells co-expressing human APP and wild type human presenilin-1 assessed as inhibition of amyloid beta42 production by ELISA Modulation of gamma-secretase expressed in CHO cells co-expressing human APP and wild type human presenilin-1 assessed as inhibition of amyloid beta42 production by ELISA	[PMID: 21873070]
CHO	IC₅₀	0.026 μM Compound: Indomethacin	In vitro inhibition of PGE-2 produced by arachidonic acid-stimulated CHO cells stably expressing human Prostaglandin G/H synthase 2 In vitro inhibition of PGE-2 produced by arachidonic acid-stimulated CHO cells stably expressing human Prostaglandin G/H synthase 2	[PMID: 9873621]
CHO	IC₅₀	0.039 μM Compound: Indomethacin	Inhibition of PGE-2 production in arachidonic acid-stimulated CHO cells expressing human Prostaglandin G/H synthase 1 Inhibition of PGE-2 production in arachidonic acid-stimulated CHO cells expressing human Prostaglandin G/H synthase 1	10.1016/S0960-894X(96)00501-X
CHO	IC₅₀	0.049 μM Compound: Indomethacin	Inhibition of PGE-2 production by arachidonic acid-stimulated CHO cells expressing human Prostaglandin G/H synthase 2 Inhibition of PGE-2 production by arachidonic acid-stimulated CHO cells expressing human Prostaglandin G/H synthase 2	10.1016/S0960-894X(96)00501-X
CHO	IC₅₀	0.018 μM Compound: Indomethacin	In vitro inhibition of the production of PGE-2 in arachidonic acid stimulated chinese hamster ovary (CHO) cells transfected with human cyclooxygenase-1 In vitro inhibition of the production of PGE-2 in arachidonic acid stimulated chinese hamster ovary (CHO) cells transfected with human cyclooxygenase-1	10.1016/S0960-894X(96)00580-X
CHO	IC₅₀	0.026 μM Compound: Indomethacin	In vitro inhibition of the production of PGE-2 in arachidonic acid stimulated chinese hamster ovary (CHO) cells transfected with human cyclooxygenase-2 In vitro inhibition of the production of PGE-2 in arachidonic acid stimulated chinese hamster ovary (CHO) cells transfected with human cyclooxygenase-2	10.1016/S0960-894X(96)00580-X
CHO	IC₅₀	0.018 μM Compound: Indomethacin	Tested in vitro for the ability to inhibit Prostaglandin G/H synthase 1 in chinese hamster ovary (CHO) cells Tested in vitro for the ability to inhibit Prostaglandin G/H synthase 1 in chinese hamster ovary (CHO) cells	10.1016/S0960-894X(96)00582-3
CHO	IC₅₀	0.026 μM Compound: Indomethacin	Tested in vitro for the ability to inhibit Prostaglandin G/H synthase 2 in chinese hamster ovary (CHO) cells Tested in vitro for the ability to inhibit Prostaglandin G/H synthase 2 in chinese hamster ovary (CHO) cells	10.1016/S0960-894X(96)00582-3
COS-7	IC₅₀	>1000 μM Compound: Indomethacin	Cytotoxicity against African green monkey COS7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against African green monkey COS7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
CV-1	EC₅₀	50 μM Compound: Indomethacin	Activation of GAL4 fused human PPARgamma ligand binding domain transfected in african green monkey CV1 cells by CAT reporter assay Activation of GAL4 fused human PPARgamma ligand binding domain transfected in african green monkey CV1 cells by CAT reporter assay	[PMID: 16643023]
DU-145	IC₅₀	>100 μM Compound: 4; Ind	Antiproliferative activity against human DU-145 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human DU-145 cells incubated for 48 hrs by MTT assay	[PMID: 36257283]
Erythrocyte	IC₅₀	0.086 μg/mL Compound: Indomethacin	Hemolytic activity in human RBC assessed as membrane mortification by absorbance method Hemolytic activity in human RBC assessed as membrane mortification by absorbance method	[PMID: 29803359]
Erythrocyte	IC₅₀	40.04 μg/mL Compound: Indomethacin	Anti-inflammatory activity in human RBC assessed as inhibition of hypotonic solution-induced hemolysis after 10 mins by spectrophotometric method Anti-inflammatory activity in human RBC assessed as inhibition of hypotonic solution-induced hemolysis after 10 mins by spectrophotometric method	[PMID: 30108827]
Erythrocyte	IC₅₀	40 μg/mL Compound: Indomethacin	Anti-inflammatory activity in human RBC assessed as inhibition of hypotonic solution-induced hemolysis after 10 mins by spectrophotometric method Anti-inflammatory activity in human RBC assessed as inhibition of hypotonic solution-induced hemolysis after 10 mins by spectrophotometric method	[PMID: 30108882]
HCT-116	IC₅₀	136.8 μM Compound: INDO	Antiproliferative activity against human HCT116 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human HCT116 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30996776]
HCT-116	EC₅₀	136.8 μM Compound: Indomethacin	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability	[PMID: 33569941]
HCT-15	IC₅₀	>1000 μM Compound: Indomethacin	Anticancer activity against human HCT15 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human HCT15 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
HEK293	IC₅₀	>50 μM Compound: C	Cytotoxicity against HEK293 cells after 72 hrs by luminescence assay Cytotoxicity against HEK293 cells after 72 hrs by luminescence assay	[PMID: 20129783]
HEK293	IC₅₀	12 μM Compound: Indometacin	Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting	[PMID: 22541068]
HEK293	IC₅₀	140 μM Compound: Indometacin	Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting	[PMID: 22541068]
HEK293	IC₅₀	41 μM Compound: Indometacin	Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting	[PMID: 22541068]
HEK293	IC₅₀	>500 μM Compound: indomethacin	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	[PMID: 23241029]
HeLa	IC₅₀	50 μM Compound: Indomethacin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 20583750]
HeLa	EC₅₀	0.14 nM Compound: 1, IMN	Agonist activity at androgen receptor (unknown origin) expressed in HeLa cells co-expressing PSA-(ARE)4-Luc13 assessed as induction of DHT-induced luciferase activity after 20 mins by luciferase reporter gene assay Agonist activity at androgen receptor (unknown origin) expressed in HeLa cells co-expressing PSA-(ARE)4-Luc13 assessed as induction of DHT-induced luciferase activity after 20 mins by luciferase reporter gene assay	[PMID: 23432095]
HeLa	IC₅₀	>50 μM Compound: Indometacin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32987314]
HeLa	IC₅₀	>50 μM Compound: Indometacin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32987314]
HeLa	IC₅₀	>50 μM Compound: Indometacin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32987314]
HepG2	IC₅₀	>50 μM Compound: C	Cytotoxicity against human HepG2 cells after 72 hrs by luminescence assay Cytotoxicity against human HepG2 cells after 72 hrs by luminescence assay	[PMID: 20129783]
HT-29	IC₅₀	1052 μM Compound: Indomethacin	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 22940705]
HT-29	IC₅₀	312.6 μM Compound: INDO	Antiproliferative activity against human HT-29 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human HT-29 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30996776]
HT-29	EC₅₀	312.6 μM Compound: Indomethacin	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability	[PMID: 33569941]
HT-29	IC₅₀	>100 μM Compound: 4; Ind	Antiproliferative activity against human HT-29 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells incubated for 48 hrs by MTT assay	[PMID: 36257283]
J774	IC₅₀	0.002 μM Compound: Indomethacin	In vitro inhibitory activity against Prostaglandin G/H synthase 1 in murine J774 cells In vitro inhibitory activity against Prostaglandin G/H synthase 1 in murine J774 cells	[PMID: 15857149]
J774	IC₅₀	0.009 μM Compound: Indomethacin	In vitro inhibitory activity against Prostaglandin G/H synthase 2 in murine J774 cells In vitro inhibitory activity against Prostaglandin G/H synthase 2 in murine J774 cells	[PMID: 15857149]
J774	IC₅₀	>100 μM Compound: Indomethacin	Cytotoxicity against mouse J774 cells assessed as cell survival after 24 hrs by MTT assay Cytotoxicity against mouse J774 cells assessed as cell survival after 24 hrs by MTT assay	[PMID: 24268542]
J774	IC₅₀	29.6 μM Compound: Indomethacin	Antiinflammatory activity in mouse J774 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method Antiinflammatory activity in mouse J774 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method	[PMID: 24268542]
J774.A1	IC₅₀	28.42 μM Compound: Indomethacin	Antiinflammatory activity in mouse J774A1 cells assessed as reduction of LPS-induced nitric oxide production treated 2 hrs before LPS addition measured after 20 hrs by using Griess reagent Antiinflammatory activity in mouse J774A1 cells assessed as reduction of LPS-induced nitric oxide production treated 2 hrs before LPS addition measured after 20 hrs by using Griess reagent	[PMID: 23688954]
J774.A1	IC₅₀	28.56 μM Compound: Indomethacin	Antiinflammatory activity in mouse J774.A1 cells assessed as inhibition of LPS-induced NO production treated 2 hrs before LPS challenge measured after 20 hrs Antiinflammatory activity in mouse J774.A1 cells assessed as inhibition of LPS-induced NO production treated 2 hrs before LPS challenge measured after 20 hrs	[PMID: 25140384]
K562	IC₅₀	190 μM Compound: Indomethacin	Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
L02	IC₅₀	>100 μM Compound: Indomethacin	Antiproliferative activity against human LO2 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human LO2 cells after 72 hrs by CCK-8 assay	[PMID: 28301815]
LNCaP	IC₅₀	>300 μM Compound: Indomethacin	Cytotoxicity against human LNCAP cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human LNCAP cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 28057407]
LNCaP	IC₅₀	238.4 μM Compound: INDO	Antiproliferative activity against human LNCAP cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human LNCAP cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30996776]
LNCaP	EC₅₀	238.4 μM Compound: Indomethacin	Antiproliferative activity against human LNCaP cells assessed as reduction in cell viability Antiproliferative activity against human LNCaP cells assessed as reduction in cell viability	[PMID: 33569941]
Macrophage	IC₅₀	22 μM Compound: indomethacin	Antiinflammatory activity in NMRI mouse macrophages assessed as inhibition of A23187-induced PGE2 release by Ellman's method Antiinflammatory activity in NMRI mouse macrophages assessed as inhibition of A23187-induced PGE2 release by Ellman's method	[PMID: 8988605]
Macrophage	IC₅₀	22 μmol Compound: indomethacin	Antiinflammatory activity in NMRI mouse macrophages assessed as inhibition of A23187-induced PGE2 release by Ellman's method Antiinflammatory activity in NMRI mouse macrophages assessed as inhibition of A23187-induced PGE2 release by Ellman's method	[PMID: 8988605]
Mast cell	IC₅₀	250 μL Compound: Indomethecin	Inhibition of compound 48/80-induced histamine release in Wistar rat peritoneal mast cells Inhibition of compound 48/80-induced histamine release in Wistar rat peritoneal mast cells	[PMID: 15270561]
Mast cell	IC₅₀	250 μM Compound: Indomethacin	Inhibition of compound 48/80-induced histamine release in Wister rat Peritoneal mast cells Inhibition of compound 48/80-induced histamine release in Wister rat Peritoneal mast cells	[PMID: 20586436]
MCF7	IC₅₀	>100 μM Compound: Indomethacin	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 20583750]
MCF7	IC₅₀	>1000 μM Compound: Indomethacin	Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
MCF7	IC₅₀	>50 μM Compound: Indometacin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32987314]
MCF7	IC₅₀	>50 μM Compound: Indometacin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32987314]
MCF7	IC₅₀	>50 μM Compound: Indometacin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32987314]
MCF7	IC₅₀	>50 μM Compound: 1	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 35468536]
MCF7	IC₅₀	>100 μM Compound: 4; Ind	Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay	[PMID: 36257283]
MDA-MB-231	IC₅₀	>100 μM Compound: Indomethacin	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 20583750]
MDCK-II	IC₅₀	235 μM Compound: Indomethacin	Inhibition of human MRP2 expressed in dog MDCK2 cells Inhibition of human MRP2 expressed in dog MDCK2 cells	[PMID: 18707884]
MIA PaCa-2	IC₅₀	>100 mM Compound: Indomethacin	Cytotoxicity against human MIAPaCa2 cells Cytotoxicity against human MIAPaCa2 cells	[PMID: 23061607]
Mononuclear cell line	IC₅₀	0.3 μM Compound: Indomethacin	Inhibition of human PGE-2 production. Inhibition of human PGE-2 production.	[PMID: 1995900]
Neutrophil	IC₅₀	>40 μM Compound: indomethacin	Antiinflammatory activity in neutrophil assessed as inhibition of fMLP induced elastase release Antiinflammatory activity in neutrophil assessed as inhibition of fMLP induced elastase release	[PMID: 17197180]
Neutrophil	IC₅₀	>40 μM Compound: indomethacin	Antiinflammatory activity in neutrophils assessed as inhibition of oxygen radical generation Antiinflammatory activity in neutrophils assessed as inhibition of oxygen radical generation	[PMID: 17197180]
Neutrophil	IC₅₀	757.99 μg/mL Compound: indomethacin	Antiinflammatory activity in human neutrophils assessed inhibition of superoxide anions production Antiinflammatory activity in human neutrophils assessed inhibition of superoxide anions production	[PMID: 19006373]
Neutrophil	IC₅₀	246.35 μM Compound: Indometacin	Antiinflammatory activity in human neutrophils assessed as inhibition of respiratory burst Antiinflammatory activity in human neutrophils assessed as inhibition of respiratory burst	[PMID: 20576329]
Neutrophil	IC₅₀	32 μM Compound: Indomethacin	Antiinflammatory activity against human neutrophil assessed as inhibition of N-formyl-l-methionyl phenylalanine/cytochalasin B-induced elastase release Antiinflammatory activity against human neutrophil assessed as inhibition of N-formyl-l-methionyl phenylalanine/cytochalasin B-induced elastase release	[PMID: 21316977]
Neutrophil	IC₅₀	38.3 μM Compound: Indomethacin	Antiinflammatory activity against human neutrophil assessed as inhibition of N-formyl-l-methionyl phenylalanine/cytochalasin B-induced superoxide anion generation by spectrophotometry Antiinflammatory activity against human neutrophil assessed as inhibition of N-formyl-l-methionyl phenylalanine/cytochalasin B-induced superoxide anion generation by spectrophotometry	[PMID: 21316977]
Neutrophil	IC₅₀	31.98 μg/mL Compound: Indomethacin	Anti-inflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release Anti-inflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release	[PMID: 21848266]
Neutrophil	IC₅₀	38.32 μg/mL Compound: Indomethacin	Anti-inflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced superoxide anion generation Anti-inflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced superoxide anion generation	[PMID: 21848266]
Neutrophil	IC₅₀	271.212 μM Compound: Indomethacin	Antiinflammatory activity in human neutrophils assessed as inhibition of opsonized zymosan A-mediated superoxide anions production by WST-1 based respiratory burst assay Antiinflammatory activity in human neutrophils assessed as inhibition of opsonized zymosan A-mediated superoxide anions production by WST-1 based respiratory burst assay	[PMID: 22437110]
PC-3	IC₅₀	>100 μM Compound: Indomethacin	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	[PMID: 20583750]
PC-3	IC₅₀	>1000 μM Compound: Indomethacin	Anticancer activity against human PC3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human PC3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
Peritoneal macrophage	IC₅₀	147.5 μM Compound: Indomethacin	Anti-inflammatory activity against LPS-stimulated mouse peritoneal macrophage assessed as reduction in nitric oxide production Anti-inflammatory activity against LPS-stimulated mouse peritoneal macrophage assessed as reduction in nitric oxide production	[PMID: 37683361]
Platelet	IC₅₀	0.1 μM Compound: Indomethacin	Inhibition of ADP-induced platelet aggregation in human platelet-rich plasma after 5 mins Inhibition of ADP-induced platelet aggregation in human platelet-rich plasma after 5 mins	[PMID: 114655]
Platelet	IC₅₀	2.8 μM Compound: Indomethacin	Inhibition of collagen-induced platelet aggregation in human platelet-rich plasma after 5 mins Inhibition of collagen-induced platelet aggregation in human platelet-rich plasma after 5 mins	[PMID: 114655]
Platelet	IC₅₀	3.2 μM Compound: Indomethacin	Inhibition of epinephrine hydrochloride-induced platelet aggregation in human platelet-rich plasma after 5 mins Inhibition of epinephrine hydrochloride-induced platelet aggregation in human platelet-rich plasma after 5 mins	[PMID: 114655]
Platelet	IC₅₀	>100 μM Compound: indomethacin	Anticoagulant activity assessed as inhibition of thrombin induced rabbit platelet aggregation Anticoagulant activity assessed as inhibition of thrombin induced rabbit platelet aggregation	[PMID: 17197180]
Platelet	IC₅₀	0.14 μM Compound: indomethacin	Anticoagulant activity assessed as inhibition of arachidonic acid induced rabbit platelet aggregation Anticoagulant activity assessed as inhibition of arachidonic acid induced rabbit platelet aggregation	[PMID: 17197180]
Platelet	IC₅₀	1.62 μM Compound: Indomethacin	Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 3 mins before arachidonic acid challenge by turbidimetric method Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 3 mins before arachidonic acid challenge by turbidimetric method	[PMID: 23639653]
Platelet	IC₅₀	0.21 μM Compound: Indomethacin	Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet-rich blood by turbidimetric method Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet-rich blood by turbidimetric method	[PMID: 8988600]
Raji	IC₅₀	>50 μM Compound: C	Cytotoxicity against human Raji cells after 72 hrs by luminescence assay Cytotoxicity against human Raji cells after 72 hrs by luminescence assay	[PMID: 20129783]
RAW	IC₅₀	15.37 μM Compound: indomethacin	Inhibition of COX2-mediated PGE2 production in LPS-stimulated mouse RAW 264.7 cells after 24 hrs by ELISA Inhibition of COX2-mediated PGE2 production in LPS-stimulated mouse RAW 264.7 cells after 24 hrs by ELISA	[PMID: 21381754]
RAW	IC₅₀	23.47 μM Compound: indomethacin	Inhibition of iNOS-mediated nitric oxide production in LPS-stimulated mouse RAW 264.7 cells treated 2 hrs before LPS challenge measured after 18 hrs by Griess reaction method Inhibition of iNOS-mediated nitric oxide production in LPS-stimulated mouse RAW 264.7 cells treated 2 hrs before LPS challenge measured after 18 hrs by Griess reaction method	[PMID: 21381754]
RAW	IC₅₀	48.89 μM Compound: indomethacin	Inhibition of iNOS in LPS-stimulated mouse RAW 264.7 cells after 2 hrs by fluorescence plate reader analysis Inhibition of iNOS in LPS-stimulated mouse RAW 264.7 cells after 2 hrs by fluorescence plate reader analysis	[PMID: 21381754]
RAW264.7	IC₅₀	52.8 nM Compound: Indomethacin	Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production after 24 hrs by Griess reagent method Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production after 24 hrs by Griess reagent method	[PMID: 19467877]
RAW264.7	IC₅₀	45.51 μM Compound: Indo	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess reagent method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess reagent method	[PMID: 19931461]
RAW264.7	IC₅₀	12.96 μM Compound: indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production by MTT assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production by MTT assay	[PMID: 20879743]
RAW264.7	IC₅₀	>100 μM Compound: indomethacin	Cytotoxicity against LPS-stimulated mouse RAW264.7 cells after 24 hrs by MTT assay Cytotoxicity against LPS-stimulated mouse RAW264.7 cells after 24 hrs by MTT assay	[PMID: 21381754]
RAW264.7	IC₅₀	>100 μM Compound: indomethacin	Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay	[PMID: 21381754]
RAW264.7	IC₅₀	12.96 μM Compound: Indomethacin	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess reaction based spectrophotometry Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess reaction based spectrophotometry	[PMID: 21807513]
RAW264.7	IC₅₀	>80 μM Compound: Indo	Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay in the absence of LPS Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay in the absence of LPS	[PMID: 22633833]
RAW264.7	IC₅₀	>80 μM Compound: Indo	Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay in the presence of LPS Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay in the presence of LPS	[PMID: 22633833]
RAW264.7	IC₅₀	20 μM Compound: Indo	Inhibition of iNOS in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production for 2 hrs by DAF-FMDA dye based fluorometric assay Inhibition of iNOS in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production for 2 hrs by DAF-FMDA dye based fluorometric assay	[PMID: 22633833]
RAW264.7	IC₅₀	148 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method	[PMID: 23566521]
RAW264.7	IC₅₀	12.1 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 23755850]
RAW264.7	IC₅₀	16.67 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method	[PMID: 24660966]
RAW264.7	IC₅₀	1.25 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay	[PMID: 24806310]
RAW264.7	IC₅₀	3.9 μM Compound: indomethacin	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of IFN-gamma plus LPS-induced NO production Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of IFN-gamma plus LPS-induced NO production	[PMID: 24960143]
RAW264.7	IC₅₀	15.8 μM Compound: Indomethacin	Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 24 hrs by Griess reagent based assay Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 24 hrs by Griess reagent based assay	[PMID: 24963714]
RAW264.7	IC₅₀	18.7 μM Compound: Indomethacin	Inhibition of LPS-induced IL-1beta production in mouse RAW264.7 cells after 24 hrs by ELISA Inhibition of LPS-induced IL-1beta production in mouse RAW264.7 cells after 24 hrs by ELISA	[PMID: 24963714]
RAW264.7	IC₅₀	1.25 μM Compound: Indomethacin	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production	[PMID: 25442320]
RAW264.7	IC₅₀	>80 μM Compound: Indo	Cytotoxicity against LPS-stimulated mouse RAW264.7 cells after 24 hrs by MTT assay Cytotoxicity against LPS-stimulated mouse RAW264.7 cells after 24 hrs by MTT assay	[PMID: 25555141]
RAW264.7	IC₅₀	>80 μM Compound: Indo	Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay	[PMID: 25555141]
RAW264.7	IC₅₀	40.3 μM Compound: Indo	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells pre-incubated for 2 hrs before LPS challenge measured 18 hrs post LPS challenge by Griess method Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells pre-incubated for 2 hrs before LPS challenge measured 18 hrs post LPS challenge by Griess method	[PMID: 25555141]
RAW264.7	IC₅₀	6.3 μM Compound: indomethacin	Antiinflammatory activity against mouse RAW264.7 cells assessed as reduction of LPS-induced NO production after 24 hrs Antiinflammatory activity against mouse RAW264.7 cells assessed as reduction of LPS-induced NO production after 24 hrs	[PMID: 25621853]
RAW264.7	IC₅₀	14.1 μM Compound: indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 1 day by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 1 day by Griess assay	[PMID: 25821895]
RAW264.7	IC₅₀	10.7 μM Compound: Indo	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs in absence of LPS by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs in absence of LPS by MTT assay	[PMID: 25881822]
RAW264.7	IC₅₀	4.5 μM Compound: Indo	Inhibition of iNOS in LPS-stimulated mouse RAW264.7 cells using L-Arginine substrate incubated for 2 hrs by fluorescence spectrometry Inhibition of iNOS in LPS-stimulated mouse RAW264.7 cells using L-Arginine substrate incubated for 2 hrs by fluorescence spectrometry	[PMID: 25881822]
RAW264.7	IC₅₀	9.2 μM Compound: Indo	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs in presence of LPS by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs in presence of LPS by MTT assay	[PMID: 25881822]
RAW264.7	IC₅₀	42.6 μM Compound: indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 25945867]
RAW264.7	IC₅₀	42.6 μM Compound: Indomethacin	Anti-inflammatory activity in mouse RAW264.7 cells assessed as LPS-stimulated inhibition of nitric oxide production incubated simultaneously with LPS for 24 hrs by Griess reagent based assay Anti-inflammatory activity in mouse RAW264.7 cells assessed as LPS-stimulated inhibition of nitric oxide production incubated simultaneously with LPS for 24 hrs by Griess reagent based assay	[PMID: 26024020]
RAW264.7	IC₅₀	16.67 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method	[PMID: 26615888]
RAW264.7	IC₅₀	12.5 μM Compound: Indomethacin	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess assay Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess assay	[PMID: 26702644]
RAW264.7	IC₅₀	42.2 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS stimulation measured after 20 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS stimulation measured after 20 hrs by Griess assay	[PMID: 26710212]
RAW264.7	IC₅₀	11.6 μM Compound: Indomethacin	Inhibition of LPS-induced NO production in mouse RAW264.7 cells incubated for 24 hrs by Griess reagent based assay Inhibition of LPS-induced NO production in mouse RAW264.7 cells incubated for 24 hrs by Griess reagent based assay	[PMID: 27276091]
RAW264.7	CC₅₀	>200 μM Compound: Indomethacin	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 27575472]
RAW264.7	IC₅₀	16.5 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reagent based assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reagent based assay	[PMID: 27575472]
RAW264.7	IC₅₀	13.2 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production after 24 hrs in presence of LPS by colorimetric analysis Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production after 24 hrs in presence of LPS by colorimetric analysis	[PMID: 27865705]
RAW264.7	IC₅₀	46.5 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by measuring nitrite accumulation by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by measuring nitrite accumulation by Griess method	[PMID: 28561586]
RAW264.7	IC₅₀	33.6 μM Compound: Indomethacin	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess assay Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess assay	[PMID: 28960979]
RAW264.7	IC₅₀	21.1 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 1 hr followed by LPS stimulation measured after 24 hrs by griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 1 hr followed by LPS stimulation measured after 24 hrs by griess assay	[PMID: 29261312]
RAW264.7	IC₅₀	33.6 μM Compound: Indomethacin	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 2 hrs followed by LPS stimulation measured after 24 hrs by Griess reagent based assay Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 2 hrs followed by LPS stimulation measured after 24 hrs by Griess reagent based assay	[PMID: 30024153]
RAW264.7	IC₅₀	>50 μM Compound: Indomethacin	Cytotoxicity against mouse RAW264.7 cells by MTT assay Cytotoxicity against mouse RAW264.7 cells by MTT assay	[PMID: 30920218]
RAW264.7	IC₅₀	41 μM Compound: Indomethacin	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production measured after 24 hrs Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production measured after 24 hrs	[PMID: 30920218]
RAW264.7	IC₅₀	>50 μM Compound: Indomethacin	Cytotoxicity against LPS-induced mouse RAW264.7 cells assessed as reduction in cell viability Cytotoxicity against LPS-induced mouse RAW264.7 cells assessed as reduction in cell viability	[PMID: 30925056]
RAW264.7	IC₅₀	>50 μM Compound: Indomethacin	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability	[PMID: 30925056]
RAW264.7	IC₅₀	45.57 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS addition and measured after 24 hrs by Griess reagent-based assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS addition and measured after 24 hrs by Griess reagent-based assay	[PMID: 30925056]
RAW264.7	CC₅₀	>50 μM Compound: Indomethacin	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability by MTT assay	[PMID: 31365251]
RAW264.7	IC₅₀	38 μM Compound: Indomethacin	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of lipopolysaccharide-induced nitric oxide production incubated for 24 hrs coincubated with LPS by Griess reagent based assay Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of lipopolysaccharide-induced nitric oxide production incubated for 24 hrs coincubated with LPS by Griess reagent based assay	[PMID: 31365251]
RAW264.7	IC₅₀	62.9 μM Compound: Indomethacin	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells incubated for 24 hrs by Griess reagent based assay Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells incubated for 24 hrs by Griess reagent based assay	[PMID: 31403786]
RAW264.7	IC₅₀	8.8 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 2 hrs followed by LPS challenge and measured after 12 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 2 hrs followed by LPS challenge and measured after 12 hrs by Griess assay	[PMID: 31573805]
RAW264.7	IC₅₀	32.2 μM Compound: Indomethacin	Inhibition of LPS-stimulated nitric oxide production in mouse RAW264.7 cells incubated for 24 hrs by Griess reagent-based assay Inhibition of LPS-stimulated nitric oxide production in mouse RAW264.7 cells incubated for 24 hrs by Griess reagent-based assay	[PMID: 32247751]
RAW264.7	IC₅₀	8.8 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production measured after 18 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production measured after 18 hrs by Griess assay	[PMID: 32520548]
RAW264.7	IC₅₀	>10 μM Compound: Ind	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by Griess reagent-based assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by Griess reagent-based assay	[PMID: 32823004]
RAW264.7	IC₅₀	>40 μM Compound: Ind	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 24 hrs in absence of LPS by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 24 hrs in absence of LPS by MTT assay	[PMID: 32823004]
RAW264.7	IC₅₀	>40 μM Compound: Ind	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 24 hrs in presence of LPS by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 24 hrs in presence of LPS by MTT assay	[PMID: 32823004]
RAW264.7	IC₅₀	24 μM Compound: Indomethacin	Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production incubated for 2 hrs followed by LPS stimulation measured after 48 hrs by MTT assay Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production incubated for 2 hrs followed by LPS stimulation measured after 48 hrs by MTT assay	[PMID: 33160760]
RAW264.7	IC₅₀	26.2 μg/mL Compound: Indomethacin	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of IFN-gamma and LPS-induced COX2 production preincubated for 2 hrs followed by IFN-gamma and LPS stimulation and measured after 16 hrs by spectrophotometric analysis Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of IFN-gamma and LPS-induced COX2 production preincubated for 2 hrs followed by IFN-gamma and LPS stimulation and measured after 16 hrs by spectrophotometric analysis	[PMID: 33422907]
RAW264.7	IC₅₀	26.3 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production	[PMID: 33422907]
RAW264.7	IC₅₀	32.3 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production for 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production for 24 hrs by Griess assay	[PMID: 33422907]
RAW264.7	IC₅₀	16.7 μM Compound: Indomethacin	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs by Griess reagent based assay Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs by Griess reagent based assay	[PMID: 33533247]
RAW264.7	IC₅₀	10.99 μM Compound: Indometacin	Antiinflammatory activity against LPS-induced mouse RAW264.7 cells assessed as inhibition of NO production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by Greiss reagent based assay Antiinflammatory activity against LPS-induced mouse RAW264.7 cells assessed as inhibition of NO production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by Greiss reagent based assay	[PMID: 34352712]
RAW264.7	IC₅₀	40.7 μM Compound: INDO	Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production incubated for 2 hrs followed by LPS stimulation for 20 hrs by Griess reagent based assay Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production incubated for 2 hrs followed by LPS stimulation for 20 hrs by Griess reagent based assay	[PMID: 35175765]
RAW264.7	IC₅₀	42.3 μM Compound: Indometacin	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS stimulation and measured after 36 hrs by Griess reagent based assay Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS stimulation and measured after 36 hrs by Griess reagent based assay	[PMID: 35512012]
RAW264.7	IC₅₀	34.28 μM Compound: Indomethacin	Inhibition of LPS induced NO production in mouse RAW264.7 cells preincubated for 1 hr followed by LPS addition and measured after 24 hrs by Griess reagent based assay Inhibition of LPS induced NO production in mouse RAW264.7 cells preincubated for 1 hr followed by LPS addition and measured after 24 hrs by Griess reagent based assay	[PMID: 35660249]
RAW264.7	IC₅₀	34.49 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated with compound for 1 hrs followed by LPS-stimulation and measured after 24 hrs by griess reagent based assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated with compound for 1 hrs followed by LPS-stimulation and measured after 24 hrs by griess reagent based assay	[PMID: 36450214]
RAW264.7	IC₅₀	0.62 μM Compound: Ind	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated NO production preincubated for 3 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated NO production preincubated for 3 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay	[PMID: 36888988]
RAW264.7	IC₅₀	56.8 μM Compound: Indo	Anti-inflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production measured after 24 hrs incubation by Griess analysis Anti-inflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production measured after 24 hrs incubation by Griess analysis	[PMID: 37224762]
RAW264.7	IC₅₀	17.64 μM Compound: Indomethacin	Anti-inflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production by ELISA analysis Anti-inflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production by ELISA analysis	[PMID: 37683361]
RAW264.7	IC₅₀	8.5 μM Compound: Indomethacin	Anti-inflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production incubated for 24 hrs by Griess reagent based assay Anti-inflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production incubated for 24 hrs by Griess reagent based assay	[PMID: 37683361]
RAW264.7	CC₅₀	>50 μM Compound: Indomethacin	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 2 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 2 hrs by MTT assay	[PMID: 38394380]
RAW264.7	IC₅₀	24 μM Compound: Indomethacin	Antiinflammatory activity in LPS induced mouse RAW264.7 cells assessed as inhibition of NO production pretreated for 2 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay Antiinflammatory activity in LPS induced mouse RAW264.7 cells assessed as inhibition of NO production pretreated for 2 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay	[PMID: 38394380]
RAW264.7	IC₅₀	37.5 μM Compound: Indomethacin	Inhibition of NO production in LPS-induced mouse RAW264.7 cells incubated for 24 hrs by absorbance based assay Inhibition of NO production in LPS-induced mouse RAW264.7 cells incubated for 24 hrs by absorbance based assay	[PMID: 39110498]
RAW264.7	IC₅₀	7.31 μM Compound: IND	Antiinflammatory activity in LPS-induced mouse RAW264.7 cells assessed as inhibition of NO production pretreated for 1 hr followed by LPS stimulation and measured after 23 hrs by Griess method Antiinflammatory activity in LPS-induced mouse RAW264.7 cells assessed as inhibition of NO production pretreated for 1 hr followed by LPS stimulation and measured after 23 hrs by Griess method	[PMID: 39140047]
RBL-1	IC₅₀	>25 μM Compound: Indomethacin	Inhibitory activity against 5-lipoxygenase of RBL-1 cell line Inhibitory activity against 5-lipoxygenase of RBL-1 cell line	[PMID: 1507204]
RBL-1	IC₅₀	>100 μM Compound: 6	Inhibition of 5-lipoxygenase in intact RBL-1 cell line Inhibition of 5-lipoxygenase in intact RBL-1 cell line	[PMID: 2115586]
RBL-1	IC₅₀	0.5 μM Compound: 6	Inhibition of Prostaglandin G/H synthase in intact RBL-1 cell line Inhibition of Prostaglandin G/H synthase in intact RBL-1 cell line	[PMID: 2115586]
RBL-1	IC₅₀	>>20 μM Compound: indomethacin	Inhibition of 5-lipoxygenase in rat RBL-1 cells Inhibition of 5-lipoxygenase in rat RBL-1 cells	[PMID: 2319562]
RBL-1	IC₅₀	0.0037 M Compound: Indomethacin	In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined	[PMID: 8254620]
RBL-1	IC₅₀	>100 μM Compound: Indomethacin	Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay	10.1016/S0960-894X(00)80396-0
RBL-1	IC₅₀	0.5 μM Compound: Indomethacin	Compound was evaluated for its inhibitory activity against CO(cyclooxygenase) in intact RBL-1 cell line assay Compound was evaluated for its inhibitory activity against CO(cyclooxygenase) in intact RBL-1 cell line assay	10.1016/S0960-894X(00)80396-0
RBL-1	IC₅₀	>100 μM Compound: Ia	Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1) Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1)	10.1016/S0960-894X(00)80450-3
RBL-1	IC₅₀	0.5 μM Compound: Ia	Tested for inhibition of cyclooxygenase (ARBC) in calcium-stimulated rat basophilic leukemia cells(RBL-1) Tested for inhibition of cyclooxygenase (ARBC) in calcium-stimulated rat basophilic leukemia cells(RBL-1)	10.1016/S0960-894X(00)80450-3
Sf21	IC₅₀	35.2 μM Compound: Indometacin	Inhibition of human recombinant COX2 expressed in baculovirus infected SF21 cell Inhibition of human recombinant COX2 expressed in baculovirus infected SF21 cell	[PMID: 20974503]
Sf9	IC₅₀	12.4 μM Compound: 1	Inhibitory concentration against human recombinant Prostaglandin G/H synthase 1 cloned and expressed in baculovirus (Sf9) Inhibitory concentration against human recombinant Prostaglandin G/H synthase 1 cloned and expressed in baculovirus (Sf9)	[PMID: 11392547]
Sf9	IC₅₀	30 nM Compound: 1	Inhibitory concentration against human recombinant Prostaglandin G/H synthase 2 cloned and expressed in baculovirus (Sf9) Inhibitory concentration against human recombinant Prostaglandin G/H synthase 2 cloned and expressed in baculovirus (Sf9)	[PMID: 11392547]
Sf9	IC₅₀	7.81 μM Compound: Indomethacin	In vitro inhibitory activity against human recombinant prostaglandin G/H synthase 2 expressed in sf-9 cells infected with baculovirus In vitro inhibitory activity against human recombinant prostaglandin G/H synthase 2 expressed in sf-9 cells infected with baculovirus	[PMID: 15026050]
Sf9	IC₅₀	0.75 μM Compound: 1, Indomethacin	Inhibition of human COX2 expressed in SF-9 insect cells assessed as conversion of [14C]-arachidonic acid to [14C]-prostaglandins preincubated for 20 mins by thin-layer chromatography analysis Inhibition of human COX2 expressed in SF-9 insect cells assessed as conversion of [14C]-arachidonic acid to [14C]-prostaglandins preincubated for 20 mins by thin-layer chromatography analysis	[PMID: 21524587]
SK-LU-1	IC₅₀	>1000 μM Compound: Indomethacin	Anticancer activity against human SKLU1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human SKLU1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
SW480	IC₅₀	>50 μM Compound: Indometacin	Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32987314]
SW480	IC₅₀	>50 μM Compound: Indometacin	Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32987314]
SW480	IC₅₀	>50 μM Compound: Indometacin	Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32987314]
TERT-RPE1	IC₅₀	>40 μM Compound: 1	Cytotoxicity against human RPE-1 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human RPE-1 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 35468536]
THP-1	IC₅₀	>10 μM Compound: indomethacin	Effect of pyrrolidine derivatives on production of eicosanoids from THP-1 cells stimulated with A-23187 using cellular assay on PGE-2, LTC-4 Effect of pyrrolidine derivatives on production of eicosanoids from THP-1 cells stimulated with A-23187 using cellular assay on PGE-2, LTC-4	[PMID: 10737736]
THP-1	IC₅₀	>10 μM Compound: indomethacin	Inhibition of arachidonic acid production from THP-1 cells stimulated with A-23187 using cellular assay Inhibition of arachidonic acid production from THP-1 cells stimulated with A-23187 using cellular assay	[PMID: 10737736]
THP-1	IC₅₀	0.0036 μM Compound: indomethacin	Effect on production of eicosanoids from THP-1 cells stimulated with A-23187 using cellular assay on PGE-2, LTC-4 Effect on production of eicosanoids from THP-1 cells stimulated with A-23187 using cellular assay on PGE-2, LTC-4	[PMID: 10737736]
THP-1	IC₅₀	>100 μM Compound: Indomethacin	In vitro effect on production of lipopolysaccharide (LPS) -induced IL1-beta in human THP-1 cells In vitro effect on production of lipopolysaccharide (LPS) -induced IL1-beta in human THP-1 cells	[PMID: 10821716]
THP-1	IC₅₀	>10000 nM Compound: Indomethacin	Concentration required to inhibit production of arachidonic acid from THP-1 cells stimulated with A-23187 Concentration required to inhibit production of arachidonic acid from THP-1 cells stimulated with A-23187	[PMID: 11229777]
THP-1	IC₅₀	3.6 nM Compound: Indomethacin	Concentration required to inhibit production of PGE-2 from THP-1 cells stimulated with A-23187 Concentration required to inhibit production of PGE-2 from THP-1 cells stimulated with A-23187	[PMID: 11229777]
THP-1	IC₅₀	>10000 nM Compound: Indomethacin	Concentration required to inhibit production of LTC4 from THP-1 cells stimulated with A-23187 Concentration required to inhibit production of LTC4 from THP-1 cells stimulated with A-23187	[PMID: 11229777]
THP-1	IC₅₀	19.37 μM Compound: Indomethacin	Anti-inflammatory activity in human THP-1 cells assessed as inhibition of LPS-stimulated NO production by ELISA analysis Anti-inflammatory activity in human THP-1 cells assessed as inhibition of LPS-stimulated NO production by ELISA analysis	[PMID: 37683361]
U-251	IC₅₀	20.45 μM Compound: Indomethacin	Anticancer activity against human U251 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human U251 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
U-937	IC₅₀	0.02 μM Compound: Indomethacin	Inhibition of COX-1 in U-937 (human lymphoma) cell microsomes. Inhibition of COX-1 in U-937 (human lymphoma) cell microsomes.	[PMID: 10576685]
U-937	IC₅₀	0.003 μM Compound: 1	Inhibition of Prostaglandin G/H synthase 1 in U-937 cells from human histiocytic lymphoma Inhibition of Prostaglandin G/H synthase 1 in U-937 cells from human histiocytic lymphoma	[PMID: 11462976]
U-937	IC₅₀	0.002 μM Compound: 1 Indomethacin	In vitro inhibitory activity against human Prostaglandin G/H synthase 1 (COX-1) in U-937 cells In vitro inhibitory activity against human Prostaglandin G/H synthase 1 (COX-1) in U-937 cells	[PMID: 12877584]
U-937	IC₅₀	0.02 μM Compound: Indomethacin	Inhibition of Prostaglandin G/H synthase 1 was measured by the inhibition of PGE-2 produced by microsomes from U937 cells incubated in low concentration of arachidonic acid Inhibition of Prostaglandin G/H synthase 1 was measured by the inhibition of PGE-2 produced by microsomes from U937 cells incubated in low concentration of arachidonic acid	[PMID: 9873621]
VCaP	IC₅₀	136.9 μM Compound: INDO	Antiproliferative activity against human VCaP cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human VCaP cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30996776]
Vero C1008	CC₅₀	>100 μM Compound: 1; INM	Cytotoxicity against African green monkey Vero E6 cells infected with SARS-CoV-2 assessed as reduction of cell viability measured after 48 hrs by MTT assay Cytotoxicity against African green monkey Vero E6 cells infected with SARS-CoV-2 assessed as reduction of cell viability measured after 48 hrs by MTT assay	[PMID: 34534839]
Vero C1008	CC₅₀	>500 μM Compound: 1; INM	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability measured after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability measured after 72 hrs by MTT assay	[PMID: 34534839]

In Vitro

Indomethacin (Indometacin) (0-150 μM; 24 h; 3LL-D122 cells) has anticancer activity in vitro^[2].
Indomethacin (Indometacin) (0-1000 μM) protects the host cells from damage caused by the virus through activates PKR, resulting in elF2α phosphorylation, and in turn shutting of translation of viral protein and inhibiting replication of the virus (IC₅₀=2μM)^[3].
Indomethacin (8 μM, 26 h) induces M1 to M2 macrophage reprogramming in RAW 264.7 cells^[4].
Indomethacin (200 μM, 5 d) induces the trans-differentiation of human adipose-derived stem cells into neurogenic cells^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Indomethacin can be used in animal modeling to construct gastrointestinal ulcer models.

Indomethacin (Indometacin) (0.01-10 mg/kg; p.o.; for 3 hours; male Sprague-Dawley rats) induces paw oedema and hyperalgesmeasurement dose-dependently reversed carrageenan-induced hyperalgesia^[1].
Indomethacin (Indometacin) (10 mg/mL; p.o.; daily, for 29 days; male C57BL/6J mice) inhibits tumor growth in vivo^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 53-86-1
Molecular Weight 357.79
Formula C₁₉H₁₆ClNO₄
SMILES

COC1=CC=C(N(C(C2=CC=C(Cl)C=C2)=O)C(C)=C3CC(O)=O)C3=C1
Synonyms

Indometacin (GMP)
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Riendeau D, et, al. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol. 1997 May;121(1):105-17. [Content Brief]

[2]. Eli Y, et, al. Comparative effects of indomethacin on cell proliferation and cell cycle progression in tumor cells grown in vitro and in vivo. Biochem Pharmacol. 2001 Mar 1;61(5):565-71. [Content Brief]

[3]. Amici C, et, al. Inhibition of viral protein translation by indomethacin in vesicular stomatitis virus infection: role of eIF2α kinase PKR. Cell Microbiol. 2015 Sep;17(9):1391-404. [Content Brief]

[4]. Luo X, Xiong H, Jiang Y, et al. Macrophage Reprogramming via Targeted ROS Scavenging and COX-2 Downregulation for Alleviating Inflammation. Bioconjug Chem. 2023;34(7):1316-1326.

[5]. Kompisch KM, Lange C, Steinemann D, et al. Neurogenic transdifferentiation of human adipose-derived stem cells? A critical protocol reevaluation with special emphasis on cell proliferation and cell cycle alterations. Histochem Cell Biol. 2010;134(5):453-468. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Indomethacin (GMP)

All Antibiotic Isoforms

All COX Isoforms

Biological Activity

Chemical Information

Purity & Documentation

References

Calculators

Help & FAQs

Indomethacin (GMP) Related Classifications

HY-14397G Related Classifications